Product Overview

Vysov-M 50/1000 Mg is a prescription oral medication formulated for the management of type 2 diabetes mellitus. Produced by Cipla Limited, the tablet combines two well‑studied antihyperglycemic agents—vildagliptin 50 mg and metformin 1000 mg—into a single dose. This fixed‑dose combination is supplied in strips containing 15 tablets, with pack options of 60, 120, or 240 tablets to suit long‑term therapy. The product is packaged to protect each tablet from moisture and light, ensuring stability throughout a shelf life of typically 24 months when stored at room temperature. Clinically, Vysov-M is indicated for patients who require both glucose‑lowering and insulin‑sensitizing effects, particularly when monotherapy with either agent does not achieve target HbA1c levels. The medication is registered with regulatory authorities in several countries and meets the quality standards set by the US FDA and the European Medicines Agency. For more information, see the NIH.

What is Vysov-M 50/1000 Mg

Vysov-M 50/1000 Mg contains vildagliptin, a selective dipeptidyl peptidase‑4 (DPP‑4) inhibitor, paired with metformin, a biguanide that reduces hepatic glucose production and improves peripheral insulin sensitivity. Vildagliptin works by blocking the DPP‑4 enzyme, which in turn prolongs the activity of incretin hormones such as GLP‑1, leading to enhanced glucose‑dependent insulin secretion and decreased glucagon release. Metformin, on the other hand, activates AMP‑activated protein kinase (AMPK), resulting in lowered hepatic gluconeogenesis and increased peripheral glucose uptake. The synergistic effect of these two mechanisms provides a dual approach to glycemic control, addressing both post‑prandial and fasting hyperglycemia. Because the two agents are released together in a single tablet, patients experience simplified dosing and improved adherence compared with taking separate pills.

Uses and Benefits

Clinicians prescribe Vysov-M to patients with type 2 diabetes who have not achieved adequate glycemic control with metformin alone or who are intolerant to higher metformin doses. The combination offers several therapeutic advantages: it reduces post‑prandial glucose spikes, lowers fasting glucose, and modestly supports weight management when compared with some sulfonylureas. Additionally, the fixed‑dose formulation decreases pill burden, which can improve patient compliance and reduce the risk of missed doses. In clinical trials, Vysov-M has demonstrated a statistically significant reduction in HbA1c by approximately 0.8 % to 1.2 % after 24 weeks, with a low incidence of hypoglycemia when used without concomitant insulin or sulfonylureas. The medication is also beneficial for patients with comorbid conditions such as hypertension or dyslipidemia, as the metformin component may contribute to modest improvements in cardiovascular risk parameters.

How It Works

The pharmacodynamic interplay between vildagliptin and metformin creates a complementary mechanism that targets glucose regulation at multiple points in the pancreatic islet and systemic circulation. By inhibiting DPP‑4, vildagliptin preserves the activity of GLP‑1, a gut hormone that stimulates insulin release from pancreatic β‑cells only when blood glucose is elevated, thereby minimizing the risk of excessive insulin secretion. Simultaneously, metformin activates AMPK in liver and skeletal muscle, leading to decreased hepatic glucose output and enhanced insulin‑sensitive glucose transport. This dual action not only flattens the post‑meal glucose excursion but also stabilizes basal glucose levels throughout the day. Moreover, the combined therapy has been shown to reduce circulating free fatty acids and triglycerides, contributing to a more favorable lipid profile. These biochemical effects translate into clinically meaningful improvements in overall glycemic control without substantially increasing the likelihood of weight gain, a common side effect of many other antidiabetic agents.

Dosage Guidelines

Adult patients are generally instructed to take one Vysov-M tablet orally once daily, preferably with the morning meal to reduce gastrointestinal discomfort. The standard starting dose is 50 mg vildagliptin combined with 1000 mg metformin, which is also the therapeutic dose used in most clinical studies. If renal function is stable (eGFR ≥60 mL/min/1.73 m²), the dose may be titrated upward to the maximum recommended strength of 50 mg/1000 mg twice daily, administered as one tablet in the morning and one in the evening, only under physician supervision. For individuals with moderate renal impairment (eGFR 45–59 mL/min/1.73 m²), the recommended frequency is once daily to avoid accumulation of metformin metabolites. Patients with severe renal dysfunction (eGFR <45 mL/min/1.73 m²) should not use Vysov-M, as the risk of lactic acidosis increases. Dosage adjustments are also advised in hepatic impairment, where the daily metformin dose should not exceed 500 mg, and in elderly populations, where caution is warranted due to polypharmacy. For detailed prescribing information, refer to the Drugs.com.

Side Effects

Like all prescription medicines, Vysov-M can cause adverse reactions, although most are mild and transient. The most frequently reported side effects include gastrointestinal disturbances such as nausea, diarrhea, abdominal discomfort, and occasional loss of appetite. These symptoms usually resolve after the first few weeks as the gut adapts to metformin. Less common but clinically important adverse events comprise hypoglycemia, particularly when Vysov-M is combined with insulin or sulfonylureas, and rare cases of pancreatitis. Very rare reports of liver enzyme elevations have prompted routine monitoring ofALT and AST in patients with pre‑existing hepatic disease. In clinical practice, clinicians advise patients to discontinue the medication and seek medical attention if they experience persistent vomiting, severe abdominal pain, or signs of lactic acidosis such as muscle weakness, rapid breathing, or unexplained fatigue. Patient education on proper hydration and avoidance of excessive alcohol intake further reduces the likelihood of serious complications.

Warnings and Precautions

Prior to initiating therapy with Vysov-M, a thorough medical evaluation is essential to identify contraindications and risk factors. The medication is contraindicated in patients with a history of hypersensitivity to vildagliptin, metformin, or any excipients, as well as in those with severe renal impairment, advanced heart failure, or active hepatic disease that predisposes to lactic acidosis. Special caution is required in individuals with renal function that fluctuates near the threshold of 45 mL/min/1.73 m², as well as in patients undergoing radiographic contrast studies or scheduled for surgery, who may need temporary discontinuation of metformin to mitigate the risk of contrast‑induced nephropathy. Pregnant or breastfeeding women should avoid Vysov-M unless the benefits clearly outweigh the risks, and healthcare providers should assess fetal safety through appropriate registries. Routine laboratory monitoring, including renal function tests and periodic assessment of electrolytes, is recommended to ensure early detection of any emerging abnormalities.

Frequently Asked Questions

1. What is the active ingredient in Vysov-M 50/1000 Mg?

Vysov-M contains 50 mg of vildagliptin and 1000 mg of metformin, acting together to improve glycemic control in type 2 diabetes.

2. How should Vysov-M be stored?

Store the tablets at room temperature, away from moisture and heat, and keep the strip sealed until use.

3. Can Vysov-M be taken with other diabetes medications?

It is generally used as monotherapy; if combined with insulin or sulfonylureas, dose adjustments may be needed to avoid hypoglycemia.

4. Is Vysov-M safe for patients with kidney disease?

It should not be used in patients with an eGFR below 45 mL/min/1.73 m²; dose reduction is recommended for moderate impairment.

5. Where can I find the full prescribing information?

Detailed prescribing details are available on the Drugs.com website and through the product’s package insert.